

- 23 Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. *Arch Intern Med.* 2010 jul 26;170(14):1191-1201.
- 24 Woodcock J. Decision on continued marketing of rosiglitazone (Avandia, Avandamet, Avandaryl). Rockville: Food and Drug Administration Center for Drug Evaluation and Research; 2010 sep 22. [www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf](http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM226959.pdf). Geraadpleegd 2011 jun 26.
- 25 Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. *JAMA.* 2007 dec 12;298(22):2634-43.
- 26 Stockl KM, Le L, Zhang S, Harada AS. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. *Pharmacoepidemiol Drug Saf.* 2009 feb;18(2):166-74.
- 27 Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *BMJ.* 2009 dec 3;339:b4731.
- 28 Ziyadeh N, McAfee AT, Koro C, Landon J, Chan KA. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. *Clin Ther.* 2009 nov;31(11):2665-77.
- 29 Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. *BMJ.* 2009 aug 18;339:b2942.
- 30 Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. *Arch Intern Med.* 2008 nov 24;168(21):2368-75.
- 31 Walker AM, Koro CE, Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. *Pharmacoepidemiol Drug Saf.* 2008 aug;17(8):760-8.
- 32 Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. *Pharmacoepidemiol Drug Saf.* 2007 okt;16(10):1065-71.
- 33 Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM. Rosiglitazone and myocardial infarction in patients previously prescribed metformin. *PLoS One.* 2009 jun 27;4(6):e6080.
- 34 Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. *Diabetes Care.* 2010 mrt;33(3):526-31.
- 35 Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. *Pharmacoepidemiol Drug Saf.* 2008 okt;17(10):989-96.
- 36 McEvoy B. Pioglitazone and rosiglitazone cardiovascular safety meta-analyses. Rockville: Food and Drug Administration Center for Drug Evaluation and Research; 2010 jul 13-14. [www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf](http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM224739.pdf). Geraadpleegd 2011 jul 26.
- 37 Slattery J. Cardiac profile of patients using rosiglitazone-containing anti-diabetes medicines: a study using the THIN database. London: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance; 2010 okt 6. [www.encepp.eu/encepp/viewResource.htm?id=1592](http://www.encepp.eu/encepp/viewResource.htm?id=1592). Geraadpleegd 2011 mei 25.
- 38 Krentz AJ. Rosiglitazone: trials, tribulations and termination. *Drugs.* 2011 jan 22;71(2):123-30.
- 39 Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Rockville: Food and Drug Administration Center for Drug Evaluation and Research; 2008 dec. [www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf). Geraadpleegd 2011 mei 24.
- 40 Guidance for Industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention – draft guidance. Rockville: Food and Drug Administration Center for Drug Evaluation and Research; 2008 feb. [www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf](http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf). Geraadpleegd 2011 mei 25.
- 41 Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus – draft. London: European Medicines Agency; 2010 jan 20. [www.emea.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2010/02/WC500073570.pdf](http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/02/WC500073570.pdf). Geraadpleegd 2011 mei 24.
- 42 Garattini S, Bertele V. Rosiglitazone and the need for a new drug safety agency. *BMJ.* 2010 okt 6;341:c5506.

## Kwantitatieve bepaling van erlotinib in plasma en weefsel

Wen Liem

Lankheet e.a. hebben als eersten een LC-MS/MS-methode ontwikkeld en gevalideerd voor de kwantitatieve analyse van erlotinib en de actieve metaboliet *O*-desmethylertotinib in humaan plasma en longtumorweefsel. Deze combinatie van vloeistofchromatografie en tandem-massaspectrometrie is ontwikkeld om kennis te vergaren over de concentraties bij patiënten met niet-kleincellig longcarcinoom. De methode is gevalideerd over een lineair bereik van 5 tot 2500 ng/mL in plasma en 5 tot 500 ng/mL in longweefsel. De kalibratiecurve in plasma is gebruikt om de longtumor-monsters te kwantificeren. De validatieresultaten laten zien dat de methode accuraat en precies is.

Kwantitatieve analyse in weefsel is belangrijk om kennis te vergaren over de opname van het geneesmiddel op de plaats van wer-

king, met name voor chemotherapeutica, welke selectief zouden moeten werken op maligne cellen en weefsels. Voor het bepalen van de dosering van chemotherapeutica die een optimaal therapeutisch effect bewerkstelligt, wordt het analyseren in weefsels steeds belangrijker.

Lankheet NA, Schaake EE, Rosing H, Burgers JA, Schellens JH, Beijnen JH, Huitema AD. Quantitative determination of erlotinib and *O*-desmethylertotinib in human EDTA plasma and lung tumor tissue. *Bioanalysis.* 2012 nov;4(21):2563-77.

Liem W. Kwantitatieve bepaling van erlotinib in plasma en weefsel.

PWetenschappelijk Platform. 2013;7:e1307.